AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19365011
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg pegaptanib sodium
Trial: 19365011
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg pegaptanib sodium
Trial: 12511360
Drug: Lidocaine 4%
RxNorm normalized name: Lidocaine 4% Patch
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine 4% unpreserved eyedrops (0.5 ml)
Trial: 10190222
Drug: Olanzapine therapy
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine therapy
Trial: 10190222
Drug: Haloperidol therapy
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol therapy
Trial: 8926734
Drug: Passive inhalation
RxNorm normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive inhalation of 100 and 200 mg freebase cocaine
Trial: 8926734
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of 1 mg cocaine hydrochloride
Trial: 2257862
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of low-dose prednisolone (0.3-0.6 mg/kg body weight)
Trial: 25966065
Drug: Intracoronary transplantation
RxNorm normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary transplantation of umbilical cord MSCs along with medication
Trial: 25966065
Drug: Medication only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication only (control group)
Trial: 27606973
Drug: Etanercept (ETN)
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept (ETN) treatment
Trial: 19228659
Drug: Combination ETN
RxNorm normalized name: ETN
DrugBank: Erythrityl tetranitrate (DB01613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination ETN and MTX treatment
Trial: 10673065
Drug: Niravoline (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niravoline (0.5 to 2 mg iv)
Trial: 10673065
Drug: Niravoline (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niravoline (1.5 mg or 2 mg iv)
Trial: 7667331
Drug: 5-HT1A agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-HT1A agonist ipsapirone (IPS)
Trial: 8452380
Drug: SDI test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDI test with adjuvant chemotherapy using tegafur and one of the following drugs: mitomycin C (MMC), adriamycin (ADM), or cisplatin (CDDP).
Trial: 3526915
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy procedure (NDT)
Trial: 18034788
Drug: SSP+ (platelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSP+ (platelet additive solution with potassium and magnesium)
Trial: 18034788
Drug: Intersol (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intersol (control platelet additive solution)
Trial: 10512132
Drug: Oral etoposide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral etoposide, 50 mg/m2, days 1‐21
Trial: 10512132
Drug: Intravenous etoposide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous etoposide, 200 mg/m2, days 1‐3
Trial: 2037844
Drug: Caffeine doses
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine doses (four different doses administered)
Trial: 20089780
Drug: Whole-grain rye
RxNorm normalized name: rice (whole grain) allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-grain rye bread (minimum 240 g/d)
Trial: 15629602
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C (MC) 15 mg/M(2)
Trial: 15629602
Drug: Porfiromycin (POR)
RxNorm normalized name: Porfiromycin
DrugBank: Porfiromycin (DB06478)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Porfiromycin (POR) 40 mg/M(2)
Trial: 12183719
Drug: Oral stimulation
RxNorm normalized name: follicle stimulating hormone / luteinizing hormone Injection [Menopur]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral stimulation program (15 minutes of stimulation of oral structures, once per day for 10 days)
Trial: 29793053
Drug: Diet with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet with sodium (0.8 g/d) and fluid (800 mL/d) restriction
Trial: 27003301
Drug: 3.75 mg
RxNorm normalized name: zopiclone 3.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 mg of Lupron
Trial: 27003301
Drug: 3.75 mg
RxNorm normalized name: zopiclone 3.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 mg of Lupron and estrogen replacement
Trial: 10995594
Drug: L-arginine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine infusion at 100 mg/kg for 30 min
Trial: 10995594
Drug: D-arginine infusion
RxNorm normalized name: 1-deamino-8-D-arginine vasopressin
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: D-arginine infusion at 100 mg/kg for 30 min
Trial: 10995594
Drug: L-arginine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine infusion at 500 mg/kg for 30 min
Trial: 10995594
Drug: D-arginine infusion
RxNorm normalized name: 1-deamino-8-D-arginine vasopressin
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: D-arginine infusion at 500 mg/kg for 30 min
Trial: 11799078
Drug: D-arginine infusion
RxNorm normalized name: 1-deamino-8-D-arginine vasopressin
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: D-arginine infusion
Trial: 9315539
Drug: Enalapril (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (0.2 to 0.3 mg x kg[-1] x d[-1], maximum 15 mg) for 10 weeks
Trial: 3511311
Drug: Insulin pump
RxNorm normalized name: insulin pump syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin pump therapy (N = 11)
Trial: 3511311
Drug: Intensive conventional
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive conventional insulin therapy (N = 11)
Trial: 18180980
Drug: Active laser
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active laser treatment (10.6 microm and 650 nm laser irradiation)
Trial: 18180980
Drug: Placebo laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo laser treatment (sham laser treatment)
Trial: 12488380
Drug: i.v. amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. amino acid infusion (4 kJ kg(‐1) h(‐1) starting 2 h before surgery)
Trial: 12488380
Drug: i.v. amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. amino acid infusion
Trial: 11332875
Drug: Rimantadine hydrochloride
RxNorm normalized name: Rimantadine Hydrochloride
DrugBank: Rimantadine (DB00478)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rimantadine hydrochloride (100 mg) - Test formulation (Rimantadin Lachema)
Trial: 9153484
Drug: Albendazole therapy
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole therapy for 1 week (n = 25)
Trial: 9153484
Drug: Albendazole therapy
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole therapy for 2 weeks (n = 25)
Trial: 7968650
Drug: HRT (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT (oral or transdermal)
Trial: 7968650
Drug: HRT (transdermal)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT (transdermal)
Trial: 7968650
Drug: HRT (oral)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT (oral)
Trial: 3478732
Drug: 3mg vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3mg vaginal tablet (Upjohn)
Trial: 28288767
Drug: IVM oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVM oral paste (0.2 mg/kg)
Trial: 28288767
Drug: IVM oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVM oral solution (0.2 mg/kg)
Trial: 28288767
Drug: IVM IM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVM IM solution (0.2 mg/kg)
Trial: 27366506
Drug: Deep breathing
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep breathing exercises, respiratory physiotherapy and O2 therapy
Trial: 29549175
Drug: Abatacept 3
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Abatacept 3 mg/kg
Trial: 29549175
Drug: Abatacept 10
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Abatacept 10 mg/kg
Trial: 21128258
Drug: Abatacept 30/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abatacept 30/10 mg/kg
Trial: 10429772
Drug: Dolasetron (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolasetron (12.5 mg)
Trial: 8779383
Drug: Test device
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test device comprising a Tuohy needle and clamp weighing 75.02 g applied to five vein sites (dorsum of arm, dorsum of hand, cephalic, ventrum of arm, cubital fossa)
Trial: 1649838
Drug: Ovine CRH
RxNorm normalized name: Ovine CRH
DrugBank: Corticorelin ovine triflutate (DB09067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovine CRH infusion (1 microgram/kg.h)
Trial: 6304787
Drug: Rolipram (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rolipram (3 mg per day)
Trial: 30975204
Drug: Mandibular advancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular advancement oral appliance (OAm) with embedded thermosensitive microchip
Trial: 30975204
Drug: Mandibular advancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular advancement oral appliance (OAm)
Trial: 29480527
Drug: Internet-based training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based training with weekly phone calls (n=232)
Trial: 27899456
Drug: Inhalation routes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation routes (smoked and vaporized)
Trial: 27899456
Drug: Oral dosing
RxNorm normalized name: oral dosing devices
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dosing
Trial: 27899456
Drug: Combined THC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined THC ≥5 μg/L plus THCCOOH/11‐hydroxy‐THC ratio <20 cutoff
Trial: 24670413
Drug: Irbesartan (angiotensin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (angiotensin II receptor blocker)
Trial: 20065047
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B daily regimen (1 mg kg(‐1) day(‐1) for 15 days)
Trial: 20065047
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B alternate day regimen (1 mg kg(‐1) on alternate days for 15 days)
Trial: 7565822
Drug: Rectal solution
RxNorm normalized name: Rectal Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal solution of apomorphine (10 or 15 mg)
Trial: 7565822
Drug: Gelatin suppository
RxNorm normalized name: Gelatin
DrugBank: Gelatin (DB11242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelatin suppository (25 and 50 mg)
Trial: 7565822
Drug: Witepsol‐H15 suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Witepsol‐H15 suppository (50 and 100 mg)
Trial: 2225702
Drug: Hydrochlorothiazide, 50
RxNorm normalized name: HydroCHLOROthiazide, 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide, 50 mg daily for 2 weeks
Trial: 2225702
Drug: Indomethacin, 50
RxNorm normalized name: Indomethacin, 50 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin, 50 mg twice a day
Trial: 30643982
Drug: SK-1202 (26
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SK-1202 (26 g/day)
Trial: 30643982
Drug: SK-1202 (39
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SK-1202 (39 g/day)
Trial: 28025352
Drug: Bupivacaine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (0.5 ml; 5 mg/ml)
Trial: 23743535
Drug: Loading (LD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading (LD group) - 3 mandatory doses of intravitreal bevacizumab
Trial: 23743535
Drug: No Loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Loading (NLD group) - no mandatory doses after baseline dose
Trial: 18940534
Drug: Coadministration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coadministration of ezetimibe 10 mg/day and simvastatin (10, 20, or 40 mg/day) for 6 weeks
Trial: 18940534
Drug: Coadministration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coadministration of ezetimibe 10 mg/day and simvastatin (40 mg/day) for 33 weeks
Trial: 18940534
Drug: Coadministration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coadministration of ezetimibe 10 mg/day and simvastatin (10 or 20 mg/day) for 53 weeks
Trial: 19526755
Drug: Astragalus Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astragalus Injection (AI)
Trial: 12480116
Drug: Coaching by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coaching by community pharmacists (3 drug coaching contacts and a 25-min take-home video)
Trial: 31721495
Drug: Conventional immediate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional immediate implant placement
Trial: 29224641
Drug: Individualized feedback
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized feedback on adherence to prescribing evidence-based therapy for physicians; weekly home visits from community health workers for patients.
Trial: 29224641
Drug: Regular updates
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular updates on advances in HF management for physicians; monthly HF educational tip sheets for patients.
Trial: 22565162
Drug: 4 l
RxNorm normalized name: PEG-4 laurate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 l Golytely single‐dosed (Go‐Si)
Trial: 22565162
Drug: 4 l
RxNorm normalized name: PEG-4 laurate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 l Golytely split‐dosed (Go‐Sp)
Trial: 22565162
Drug: 238 g
RxNorm normalized name: AVOBENZONE 3.371 g in 112.38 g / OXYBENZONE 6.743 g in 112.38 g / OCTINOXATE 8.429 g in 112.38 g / HOMOSALATE 11.238 g in 112.38 g / OCTISALATE 5.619 g in 112.38 g TOPICAL CREAM [Advanced Sun Resistance SPF 30]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 238 g MiraLAX in 64 oz of Gatorade single‐dosed (Mlax‐Si)
Trial: 17438555
Drug: Family-based group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based group treatment (15 separate sessions for parents and children)
Trial: 15960271
Drug: Morphine 0.4
RxNorm normalized name: morphine 0.4 mg/mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 0.4 mg/ml with 6 microg/kg naloxone
Trial: 15960271
Drug: 0.4 mg/ml
RxNorm normalized name: thymol 0.4 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg/ml morphine
Trial: 11922881
Drug: Indoleamine (via
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoleamine (via tryptophan depletion) plus catecholamine (via alpha‐methyl‐paratyrosine administration) depletion
Trial: 11922881
Drug: Indoleamine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoleamine plus sham (via diphenhydramine administration) catecholamine depletion
Trial: 9704689
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor ramipril (2.5 to 20 mg/day)
Trial: 26349548
Drug: Concomitant administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concomitant administration of RV1 and OPV (monovalent, bivalent, or trivalent)
Trial: 26349548
Drug: Staggered administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Staggered administration of RV1 and OPV (≥1 day apart)
Trial: 23349519
Drug: Levodopa (6.65
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa (6.65 ± 1.66 mg/kg/d)
Trial: 17522235
Drug: Adjuvant hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjuvant hormonal and polychemotherapy therapy
Trial: 15203440
Drug: 1.7 g
RxNorm normalized name: Vaporizer 1.7 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.7 g naltrexone implant
Trial: 15203440
Drug: 3.4 g
RxNorm normalized name: psyllium 3.4 g oral wafer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.4 g naltrexone implant
Trial: 12376047
Drug: Laser light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser light treatment (wavelength 810 nm, dose 4 J/cm2) in Group A
Trial: 12376047
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (quasi-laser therapy) in Group B
Trial: 1971199
Drug: 1.5 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg.kg‐1 IV lidocaine administered 1-4 minutes before intubation
Trial: 6771829
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg methylphenidate
Trial: 24034834
Drug: 16 G
RxNorm normalized name: Maltsupex, 16 g/15 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 G biopsy needles (Group A)
Trial: 24034834
Drug: 18 G
RxNorm normalized name: flotufolastat F 18 gallium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 G biopsy needles (Group B)
Trial: 2452997
Drug: Midodrine (alpha-adrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midodrine (alpha-adrenergic agonist)
Trial: 2508049
Drug: piperacillin, 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: piperacillin, 300 mg/kg/day plus tobramycin, 10 and more mg/kg/day for 14 days
Trial: 2508049
Drug: ceftazidime, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ceftazidime, 150 mg/kg/day for 14 days
Trial: 25589624
Drug: Cyclophosphamide +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide + Veliparib (60 mg orally once daily)
Trial: 25589624
Drug: Cyclophosphamide alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide alone (50 mg orally once daily)
Trial: 23936331
Drug: Urinary betaine
RxNorm normalized name: betaine
DrugBank: Betaine (DB06756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Urinary betaine excretion in patients with diabetes mellitus (n = 264)
Trial: 23936331
Drug: Urinary betaine
RxNorm normalized name: betaine
DrugBank: Betaine (DB06756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Urinary betaine excretion
Trial: 23936331
Drug: Baseline betaine
RxNorm normalized name: betaine
DrugBank: Betaine (DB06756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Baseline betaine excretion
Trial: 21882087
Drug: Low-contrast dose
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-contrast dose protocol (P(low)): iohexol-350 [0.7 ml/kg body weight (BW)] during 9 s
Trial: 21882087
Drug: Conventional protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional protocol (P(conv)): iohexol-350 (1.0 ml/kg BW) during 15 s
Trial: 15193740
Drug: Gliclazide 80
RxNorm normalized name: gliclazide 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide 80 mg (formulation 1)
Trial: 15193740
Drug: Gliclazide 80
RxNorm normalized name: gliclazide 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide 80 mg (formulation 2)
Trial: 11331167
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg rofecoxib capsule po 1 hour before induction of anesthesia
Trial: 11331167
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule po 1 hour before induction of anesthesia
Trial: 9154397
Drug: Topical terbinafine
RxNorm normalized name: terbinafine Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical terbinafine 1% solution
Trial: 7700076
Drug: cilazapril 2.5
RxNorm normalized name: cilazapril 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cilazapril 2.5 mg once daily
Trial: 7700076
Drug: cilazapril 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cilazapril 5.0 mg once daily
Trial: 27001782
Drug: Vibrating massage
RxNorm normalized name: VIBRATING DEVICE,CONSTIPATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibrating massage of all masseter muscles, tourmaline ceramic on the joint area, and local physical therapy.
Trial: 23437055
Drug: MYM-V101 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MYM-V101 vaccine at 10 μg/dose
Trial: 23437055
Drug: MYM-V101 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MYM-V101 vaccine at 50 μg/dose
Trial: 23437055
Drug: MYM-V101 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MYM-V101 vaccine (both doses)
Trial: 23437055
Drug: MYM-V101 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MYM-V101 vaccine (high dose)
Trial: 18834276
Drug: Group therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group therapy for complicated grief